The combination of pertuzumab with trastuzumab was not effective in decreasing cell growth below 50% compared to DMSO + IgG control in both cell lines, which is in contrast with their effect on HER2 over-expressed breast cancer cell lines [26], correlated with the inability to decrease pHER2 and to downregulate HER2 at 24 h in these cells (Fig. 2A, B). Here, ERBB2 is linked to breast carcinoma.